AQST Stock Forecast & Price Target

Aquestive Therapeutics Inc. demonstrates a promising outlook due to its innovative product pipeline, particularly the anticipated contributions from Anaphylm sales, which are expected to positively impact revenue after its market entry in the second half of 2026. The FDA's granting of Orphan Drug Exclusivity to Libervant enhances its competitive position and validates its easy-to-use buccal administration method over traditional routes, potentially expanding its market reach beyond the current pediatric focus. Additionally, the successful completion of adult clinical trials for Anaphylm and positive FDA feedback for the New Drug Application underpin a favorable trajectory for new product launches and revenue growth in the near future.

Aquestive Therapeutics Inc is facing significant challenges that contribute to a negative outlook on its stock, primarily due to a faster-than-anticipated decline of its Suboxone franchise due to generic competition and potential delays in the rollout of Libervant in the U.S. market. The company’s revenue guidance for 2025, projected between $47 million and $66 million, coupled with an estimated net loss per share of $0.61, highlights ongoing financial struggles that exceed prior loss expectations. Additionally, regulatory complications, particularly concerning the FDA's approval of Libervant for younger patients and potential market penetration issues for its product pipeline, amplify the risks to the company’s growth trajectory.